Pasithea Therapeutics Corp (KTTA) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.51 (+0.85%), Market cap $0.02B, 52-week low–high $0.29 ~ $1.47.
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also i
Financial statements, price targets, institutional (13F) holdings and related news for Pasithea Therapeutics Corp are updated in real time on BlackAll Trade.
Pasithea Therapeutics Corp trades at $0.51 (+0.85%). Real-time quotes and charts are available on BlackAll Trade.
Pasithea Therapeutics Corp has a market cap of about $0.02B.
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and canc